Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIB | P23284 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | PPID | Q08752 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12643750 | 0.89 | PPIB (0.73) | PPIBRAB9APPIDALDH1A1HPGD | |
| SCHEMBL14617666 | 0.86 | PPIB (0.85) | PPIBRAB9APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL15832190 | 0.86 | PPID (0.73) | PPIBRAB9APPIDEPHX2SMN1; SMN2 | |
| SCHEMBL14617668 | 0.85 | PPIB (0.59) | PPIBRAB9APPIDEPHX2POLB | |
| SCHEMBL15832157 | 0.85 | PPID (0.75) | PPIBRAB9APPIDEPHX2SMN1; SMN2 | |
| SCHEMBL2036896 | 0.79 | PPIB (1.00) | PPIBRAB9APPIDPOLBSMN1; SMN2 | |
| SCHEMBL16270323 | 0.78 | PPID (0.57) | PPIBRAB9APPIDEPHX2POLB | |
| SCHEMBL15832148 | 0.76 | PPIB (0.52) | PPIBRAB9AEPHX2POLBSMN1; SMN2 | |
| SCHEMBL14617670 | 0.75 | PPID (0.53) | PPIBRAB9APPIDSMN1; SMN2ALDH1A1 | |
| SCHEMBL15022357 | 0.75 | RAB9A (0.77) | RAB9AEPHX2POLBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-06-26 | — | — | US | disclosed |
| US-20130018044-A1 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | FKBP3, FKBP4, FKBP5 | PPIB 51/4885RAB9A 4312/4885PPID 73/4885 |
| US-20130018044-A1 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | FKBP3, FKBP4, FKBP5 | PPIB 51/4885RAB9A 4312/4885PPID 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.